Kaposi's Sarcoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major kaposi's sarcoma markets reached a value of US$ 109.4 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 160.2 Million by 2034, exhibiting a growth rate (CAGR) of 3.53% during 2024-2034.
The Kaposi's sarcoma market has been comprehensively analyzed in IMARC's new report titled "Kaposi's Sarcoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Kaposi's sarcoma (KS) refers to a type of cancer that affects the cell linings of the blood and lymph vessels. The symptoms of the ailment depend on the location and extent of the lesions. The most typical indication is the development of red or purple patches and nodules on the skin or mucous membranes, which may be painless or tender. These lesions can vary in size as well as number and may be flat or raised. The condition can also affect internal organs, leading to symptoms such as shortness of breath, chest pain, abdominal pain, nausea, vomiting, etc. In cases of HIV-associated Kaposi's sarcoma, the disease may be accompanied by other indications of advanced HIV infection, including fever, night sweats, weight loss, fatigue, etc. The diagnosis involves a physical examination and a biopsy of the affected tissue. The biopsy sample is examined under a microscope to look for the characteristic spindle-shaped cells that are seen in KS. Several additional procedures are performed to determine the extent of the ailment, such as imaging studies like X-rays, CT scans, or MRI scans. Various blood tests are also advised to check for infection with Kaposi's sarcoma-associated herpesvirus.
The increasing cases of human herpesvirus 8 (HHV-8) infections that affect the cell linings of blood vessels and lymphatic vessels, leading to the formation of lesions, are primarily driving the Kaposi's sarcoma market. Furthermore, the widespread adoption of targeted therapy drugs, such as bevacizumab or pazopanib, to target specific proteins or pathways that are involved in the development of the ailment is acting as another significant growth-inducing factor. Additionally, the inflating utilization of photodynamic therapy as a treatment option, which uses a special light and a photosensitizing drug to destroy cancer cells, is further augmenting the market growth. Moreover, the escalating demand for topical treatments, including imiquimod cream and retinoids, to treat lesions on the skin or mucous membranes caused by KS is also creating a positive outlook for the market. Apart from this, the introduction of numerous advanced imaging techniques, such as magnetic resonance imaging (MRI) and positron emission tomography (PET), which have greatly improved the ability to detect as well as monitor lesions in various parts of the body, including soft tissues, bones, lymph nodes, etc., is expected to drive the Kaposi's sarcoma market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the Kaposi's sarcoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Kaposi's sarcoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Kaposi's sarcoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Kaposi's sarcoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Kaposi's sarcoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Kaposi's sarcoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Kaposi's sarcoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Kaposi's sarcoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Kaposi's sarcoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Kaposi's sarcoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of Kaposi's sarcoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Kaposi's sarcoma by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of Kaposi's sarcoma by type across the seven major markets?
How many patients are diagnosed (2018-2034) with Kaposi's sarcoma across the seven major markets?
What is the size of the Kaposi's sarcoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Kaposi's sarcoma?
What will be the growth rate of patients across the seven major markets?
Kaposi's Sarcoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Kaposi's sarcoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Kaposi's sarcoma market?
What are the key regulatory events related to the Kaposi's sarcoma market?
What is the structure of clinical trial landscape by status related to the Kaposi's sarcoma market?
What is the structure of clinical trial landscape by phase related to the Kaposi's sarcoma market?
What is the structure of clinical trial landscape by route of administration related to the Kaposi's sarcoma market?
The Kaposi's sarcoma market has been comprehensively analyzed in IMARC's new report titled "Kaposi's Sarcoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Kaposi's sarcoma (KS) refers to a type of cancer that affects the cell linings of the blood and lymph vessels. The symptoms of the ailment depend on the location and extent of the lesions. The most typical indication is the development of red or purple patches and nodules on the skin or mucous membranes, which may be painless or tender. These lesions can vary in size as well as number and may be flat or raised. The condition can also affect internal organs, leading to symptoms such as shortness of breath, chest pain, abdominal pain, nausea, vomiting, etc. In cases of HIV-associated Kaposi's sarcoma, the disease may be accompanied by other indications of advanced HIV infection, including fever, night sweats, weight loss, fatigue, etc. The diagnosis involves a physical examination and a biopsy of the affected tissue. The biopsy sample is examined under a microscope to look for the characteristic spindle-shaped cells that are seen in KS. Several additional procedures are performed to determine the extent of the ailment, such as imaging studies like X-rays, CT scans, or MRI scans. Various blood tests are also advised to check for infection with Kaposi's sarcoma-associated herpesvirus.
The increasing cases of human herpesvirus 8 (HHV-8) infections that affect the cell linings of blood vessels and lymphatic vessels, leading to the formation of lesions, are primarily driving the Kaposi's sarcoma market. Furthermore, the widespread adoption of targeted therapy drugs, such as bevacizumab or pazopanib, to target specific proteins or pathways that are involved in the development of the ailment is acting as another significant growth-inducing factor. Additionally, the inflating utilization of photodynamic therapy as a treatment option, which uses a special light and a photosensitizing drug to destroy cancer cells, is further augmenting the market growth. Moreover, the escalating demand for topical treatments, including imiquimod cream and retinoids, to treat lesions on the skin or mucous membranes caused by KS is also creating a positive outlook for the market. Apart from this, the introduction of numerous advanced imaging techniques, such as magnetic resonance imaging (MRI) and positron emission tomography (PET), which have greatly improved the ability to detect as well as monitor lesions in various parts of the body, including soft tissues, bones, lymph nodes, etc., is expected to drive the Kaposi's sarcoma market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the Kaposi's sarcoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Kaposi's sarcoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Kaposi's sarcoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Kaposi's sarcoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Kaposi's sarcoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Kaposi's sarcoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Kaposi's sarcoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Kaposi's sarcoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Kaposi's sarcoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Kaposi's sarcoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of Kaposi's sarcoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Kaposi's sarcoma by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of Kaposi's sarcoma by type across the seven major markets?
How many patients are diagnosed (2018-2034) with Kaposi's sarcoma across the seven major markets?
What is the size of the Kaposi's sarcoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Kaposi's sarcoma?
What will be the growth rate of patients across the seven major markets?
Kaposi's Sarcoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Kaposi's sarcoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Kaposi's sarcoma market?
What are the key regulatory events related to the Kaposi's sarcoma market?
What is the structure of clinical trial landscape by status related to the Kaposi's sarcoma market?
What is the structure of clinical trial landscape by phase related to the Kaposi's sarcoma market?
What is the structure of clinical trial landscape by route of administration related to the Kaposi's sarcoma market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 KAPOSI'S SARCOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 KAPOSI'S SARCOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 KAPOSI'S SARCOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 KAPOSI'S SARCOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 KAPOSI'S SARCOMA - UNMET NEEDS
10 KAPOSI'S SARCOMA - KEY ENDPOINTS OF TREATMENT
11 KAPOSI'S SARCOMA - MARKETED PRODUCTS
11.1 List of Kaposi's Sarcoma Marketed Drugs Across the Top 7 Markets
11.1.1 Taxol (Paclitaxel) - Cheplapharm Arzneimittel
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Panretin (Alitretinoin topical) - Ligand Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Pomalyst (Pomalidomide) - Celgene Corporation
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Doxil (Doxorubicin liposomal) - ALZA
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Intron A (Interferon alpha-2b) - Merck & Co
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 KAPOSI'S SARCOMA - PIPELINE DRUGS
12.1 List of Kaposi's Sarcoma Pipeline Drugs Across the Top 7 Markets
12.1.1 sEphB4 HSA - VasGene Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Aldoxorubicin - ImmunityBio
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. KAPOSI'S SARCOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. KAPOSI'S SARCOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 KAPOSI'S SARCOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Kaposi's Sarcoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Kaposi's Sarcoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Kaposi's Sarcoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Kaposi's Sarcoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Kaposi's Sarcoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Kaposi's Sarcoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Kaposi's Sarcoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Kaposi's Sarcoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Kaposi's Sarcoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Kaposi's Sarcoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Kaposi's Sarcoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Kaposi's Sarcoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Kaposi's Sarcoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Kaposi's Sarcoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Kaposi's Sarcoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Kaposi's Sarcoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Kaposi's Sarcoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Kaposi's Sarcoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Kaposi's Sarcoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Kaposi's Sarcoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Kaposi's Sarcoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Kaposi's Sarcoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Kaposi's Sarcoma - Access and Reimbursement Overview
16 KAPOSI'S SARCOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 KAPOSI'S SARCOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 KAPOSI'S SARCOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 KAPOSI'S SARCOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 KAPOSI'S SARCOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 KAPOSI'S SARCOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 KAPOSI'S SARCOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 KAPOSI'S SARCOMA - UNMET NEEDS
10 KAPOSI'S SARCOMA - KEY ENDPOINTS OF TREATMENT
11 KAPOSI'S SARCOMA - MARKETED PRODUCTS
11.1 List of Kaposi's Sarcoma Marketed Drugs Across the Top 7 Markets
11.1.1 Taxol (Paclitaxel) - Cheplapharm Arzneimittel
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Panretin (Alitretinoin topical) - Ligand Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Pomalyst (Pomalidomide) - Celgene Corporation
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Doxil (Doxorubicin liposomal) - ALZA
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Intron A (Interferon alpha-2b) - Merck & Co
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 KAPOSI'S SARCOMA - PIPELINE DRUGS
12.1 List of Kaposi's Sarcoma Pipeline Drugs Across the Top 7 Markets
12.1.1 sEphB4 HSA - VasGene Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Aldoxorubicin - ImmunityBio
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. KAPOSI'S SARCOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. KAPOSI'S SARCOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 KAPOSI'S SARCOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Kaposi's Sarcoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Kaposi's Sarcoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Kaposi's Sarcoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Kaposi's Sarcoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Kaposi's Sarcoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Kaposi's Sarcoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Kaposi's Sarcoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Kaposi's Sarcoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Kaposi's Sarcoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Kaposi's Sarcoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Kaposi's Sarcoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Kaposi's Sarcoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Kaposi's Sarcoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Kaposi's Sarcoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Kaposi's Sarcoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Kaposi's Sarcoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Kaposi's Sarcoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Kaposi's Sarcoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Kaposi's Sarcoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Kaposi's Sarcoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Kaposi's Sarcoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Kaposi's Sarcoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Kaposi's Sarcoma - Access and Reimbursement Overview
16 KAPOSI'S SARCOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 KAPOSI'S SARCOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 KAPOSI'S SARCOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
